Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and ...

KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, has discovered how cancer cells can ...

Strong demand from utility-scale projects, rooftop targets and ALMM mandates drove expansion, with cumulative capacity ...

According to a team of researchers at Baylor College of Medicine, Tongji University and collaborating institutions, weaning ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

According to a team of researchers at Baylor College of Medicine, Tongji University and collaborating institutions, weaning or switching from milk ...

Silicon nanotube arrays deliver functional mRNA into human pluripotent stem cells for the first time, achieving up to 64% transfection without compromising stem cell identity.

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...

India added 119 GW of solar module capacity and over 9 GW of cell capacity in 2025, bringing total capacities to about 210 GW and 27 GW, respectively, according to Mercom India. Growth was driven by ...

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric ...